Predicting the future of cardiovascular risk prediction by Banerjee, A
TITLE PAGE 
Title: Predicting the future of cardiovascular risk prediction 
 
Author names and affiliations: 
Amitava Banerjee1    ami.banerjee@ucl.ac.uk 
 
1Farr Institute of Health Informatics Research, University College London, London 
 
Corresponding author: Dr Amitava Banerjee 
Present address: Farr Institute of Health Informatics Research 
222 Euston Road 
London 
UK 
NW1 2DA 
Tel: 02035495449 
Email: ami.banerjee@ucl.ac.uk 
 
Word count: 822 words 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicting the future of cardiovascular risk prediction 
 
The iconic Framingham Heart Study paved the way for many prospective 
epidemiologic cohort studies of cardiovascular disease (CVD) around the world, and 
the subsequent development of tools which can predict risk of future disease. There 
have been tools for a broad spectrum of outcomes from absolute CVD risk at varying 
time points to lifetime risk(1) and vascular age(2). Multiple scores for incident CVD 
have been derived and validated, and adopted in consensus guidelines for use in 
routine practice. 
 
However, the major burden of CVD events occurs in individuals who have already 
been diagnosed with recurrent disease, yet even in high-income countries, adherence 
and persistence to secondary prevention drugs is far from optimal(3). By comparison 
with incident CVD, relatively few risk prediction tools are available for clinicians to use 
in secondary prevention. These patients have a wide range of absolute risk for CVD. 
Moreover, many of the scores for this purpose have been developed in hospital 
populations rather than primary care, where they would arguably have more utility. In 
this issue of Heart, Poppe and colleagues, report a novel prediction tool (PREDICT-
CVD) for secondary CVD prevention, derived using data from 24,927 patients in the 
New Zealand primary care setting with 1,480 CVD events within 2 years of a baseline 
CVD risk assessment. Both discrimination and calibration of PREDICT-CVD were very 
good, although it overestimated risk in the highest-risk individuals, particularly those 
with heart failure [Poppe et al. Heart 2017]. 
 
There are several key principles which the PREDICT-CVD score illustrates. First, the 
authors confirm that locally derived scores are likely to have the best performance in 
that population. Such scores are more likely to be taken up by clinicians. On the other 
hand, more universal scores may be required for the purpose of national or cross-
national implementation and monitoring. Therefore, it is always important to consider 
the characteristics of the target population for the risk prediction tool, as well as the 
clinicians and the context in which the score will be used. Second, simple risk 
prediction tools derived from routine clinical data have as much clinical utility, if not 
more, than more complex tools involving biomarkers and genomics. Third, across 
different CVD types, the use of electronic health records rather than traditional 
research cohort study designs is increasing and probably have greater application in 
clinical practice(4).    
 
However, there are four issues which still remain. First, in PREDICT-CVD, a CVD 
event was defined as MI, ischaemic or haemorrhagic stroke, or CVD death, defined 
from ICD-10-AM codes. Therefore, the score is concerned with individuals with 
atherosclerotic disease. Given the increasing importance of heart failure, atrial 
fibrillation and other comorbidities as well as the growing number of risk prediction 
tools for different forms of CVD, there may be a role for simplification of tools for 
clinicians and patients in order to look at the possibility of a composite score for a 
broader range of CVD event types. 
 
Second, the use of the PREDICT-CVD score and other scores offers the promise of 
personalisation of drug and lifestyle therapy(5), but, in reality, may not have a 
substantial impact on outcomes. In this same population in New Zealand, persistence 
to secondary prevention medications has already been studied. Among patients 
untreated at baseline, individuals with prior CVD had the highest dispensing rates for 
blood-pressure-lowering and lipid-lowering, and incrementally higher dispensing rates 
were noted as CVD risk group increased. Given that over half of all CVD events 
occurred in the 20% of the population at highest risk of future CVD, it is reasonable to 
use the PREDICT-CVD score in these patients to optimise their management. 
However, the same study also showed that about two-thirds of patients with prior CVD 
were already using appropriate medications at baseline, and continued to do so after 
3 years of follow-up(6). In some subpopulations, such as elderly, there is evidence 
that due to high absolute risk reductions, treating all patients may be more beneficial 
than risk prediction-based treatment for secondary CVD prevention(7).    
 
Third, risk prediction is only one stage in the approach to CVD management and 
should not be considered in isolation. Communication and treatment to mitigate the 
predicted risk follow from risk prediction. However, the impact of clinical prediction 
rules and risk prediction tools is rarely evaluated(8). 
 
Finally, at present, the potential of EHR for development and validation of risk 
prediction tools across diseases remains largely untapped with few multi-centre 
studies and even fewer with validation across sites(9). Although the PREDICT-CVD 
initiative uses routine clinical data, the current model uses a derivation cohort which 
recruited from 2006 to 2012, and a validation cohort which was from 2005 to 2010. 
The future scenario may well be real-time data analytics to use in a contemporaneous 
population. In an era of advanced big data analytics, machine learning and artificial 
intelligence(10) offer new ways of predicting risk. The current paradigm of multi-
variable Cox regression models informed by prospective cohort studies testing the 
incremental gain of novel biomarkers one-by-one needs to be challenged.  
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